When does dolutegravir lose exclusivity in Europe?
Dolutegravir (DTG) exclusivity timing in Europe depends on the specific product, marketing authorization, and the type of exclusivity being considered (for example, patent expiry vs. regulatory data protection). The provided information does not include dates or a specific dossier/patent list for Europe, so the exact “loss of exclusivity” date cannot be determined from the current context.
What does “loss of exclusivity” usually mean for dolutegravir in Europe?
In Europe, market entry before or after generic competition typically turns on several legal barriers that can differ by country and by medicine:
- Patent expiry (including any patent terms/extensions and how courts rule on validity/infringement).
- Regulatory data protection/exclusivity tied to the centralized marketing authorization and how long originator data cannot be relied on by later applicants.
- Patent “evergreening” strategies (for example, new formulations or combinations) that can delay generic entry even after earlier patents expire.
If you tell me the brand name (or the dose/form) and whether you mean patent expiry or regulatory exclusivity, I can map the answer to the right concept.
Does dolutegravir lose exclusivity at the same time across EU countries?
Not always. Even with an EU-wide marketing authorization, generic launch timing can vary because enforcement and patent coverage can differ by jurisdiction, and companies sometimes launch country-by-country after successfully navigating local patent litigation and clearance.
Which version matters: dolutegravir alone vs. fixed-dose combinations?
Exclusivity can differ for:
- Dolutegravir as a standalone medicine.
- Fixed-dose combinations that include dolutegravir (combination products can have different IP and regulatory protection timelines than the single-entity drug).
If your question is about a particular combination (for example, with other antiretrovirals), the exclusivity outcome can change.
Why are companies watching dolutegravir exclusivity in Europe?
Dolutegravir is a high-volume antiretroviral, so loss of exclusivity can open the door to:
- Generic and/or biosimilar competition (for biosimilars, that is typically a different product class than DTG).
- Lower prices in national formularies.
- Expanded access depending on tender and procurement cycles.
What I need to give you an exact Europe date
To answer with a specific “loss of exclusivity” date for dolutegravir in Europe, I need at least one of the following:
- The dolutegravir product/brand name and dosage form (or the fixed-dose combination name).
- The target country (EU member states can differ in practical entry).
- Whether you want patent expiry or regulatory exclusivity/data protection.
Share that detail and I’ll narrow it to the relevant exclusivity mechanism and the most likely timeline.
Sources
No sources were provided in the prompt, so none could be cited.